Oncology · 3 h ago
MASSIN-K score stratifies recurrence and mortality risk in papillary thyroid cancer
A prognostic score incorporating Ki-67 was developed in a cohort of 8,540 patients with papillary thyroid carcinoma who underwent curative surgery. The score separated patients into groups with differing 10-year recurrence-free and cause-specific survival, but external validation is still needed.
- Score developed in 8,540 surgically treated patients
- Ki-67 was included with clinical and pathological factors
- High-score groups had lower 10-year survival measures
- External validation is required
Researchers analyzed 8,540 patients with papillary thyroid carcinoma treated with curative surgery, with a median follow-up of 8.7 years. Using multivariable Cox regression, they developed the MASSIN-K scoring system, which incorporates Ki-67 labeling index alongside clinical and pathological factors. During follow-up, 368 patients had local recurrence, 125 had distant recurrence, and 22 died from carcinoma.
Ten-year local recurrence-free survival was 98.1%, 95.2%, and 84.5% in low-, intermediate-, and high-score groups, respectively. Corresponding distant recurrence-free survival was 99.6%, 97.9%, and 85.8%. For the overall cause-specific survival score, 10-year survival was 100%, 99.8%, and 97.1% across the three risk groups.
The findings suggest that adding Ki-67 may help distinguish prognosis after surgery, particularly among higher-scoring patients. However, this was a score-development study, and the authors state that external validation is required; the results alone do not establish how the score should guide clinical decisions.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
World Journal of Surgery: Development of a Prognostic Score for Papillary Thyroid Carcinoma Incorporating Ki‐67 Labeling Index: MASSIN‐K ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.